Financials data is unavailable for this security.
Cash flow in USDView more
In 2023, cash reserves at Cellectar Biosciences Inc fell by 10.30m. Cash Flow from Financing totalled 22.94m or -- of revenues. In addition the company used 32.38m for operations while cash used for investing totalled 864.04k.
Cash flow per share | -3.03 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 0.789 |
---|---|
Tangible book value per share | 0.789 |
More ▼
Balance sheet in USDView more
Current ratio | 2.54 |
---|---|
Quick ratio | -- |
Total debt/total equity | 0.00 |
---|---|
Total debt/total capital | 0.00 |
More ▼